Company news
ProtoKinetix, Inc. news in 2017
ProtoKinetix, Inc.'s news releases, calls and decks from 2017, newest first.
The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to Immunotherapy
November 16, 2017
Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery
October 17, 2017
ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP™ in Immune Cell Cryopreservation Testing
June 5, 2017
ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP™
May 24, 2017
ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP™ PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes
March 9, 2017
ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration
February 7, 2017
ProtoKinetix Announces Investigator Sponsored Human Clinical Trial Application Using AAGP™ Has Been Approved by Health Canada
January 24, 2017
ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP™ in the Treatment of Type 1 Diabetes
January 17, 2017